NCT06342141View on ClinicalTrials.gov

Empagliflozin for No-reflow Phenomenon in PCI for STEMI

PHASE2RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

October 15, 2025

Conditions
STEMINo-Reflow Phenomenon
Interventions
DRUG

Empagliflozin 25 milgrams (Mg)

Load dose

DRUG

Empagliflozin 10 Mg

Maintenance dose

Trial Locations (1)

14080

RECRUITING

National Institute of Cardiology, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cardiologia Ignacio Chavez

OTHER